Shares of Roivant Sciences (ROIV) and Arbutus Biopharma (ABUS) moved higher while Moderna (MRNA) sold off after a judge issued a lipid nanoparticle claim construction order for the patent infringement case between Roivant and Arbutus versus Moderna. Jefferies says the judge sided with Roivant and Arbutus on three of four claims, including the key ‘378 patent.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ROIV:
- Roivant Sciences board approves of repurchase program up to $1.5B
- Roivant Sciences announces NEPTUNE study met primary efficacy endpoint
- Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million
- Roivant Sciences to replace Sunrun in the S&P 400 at open on 4/1
- Sunrun to replace PGT Innovations in the S&P 600 at open on 4/1